ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization

ReForm Biologics inks evaluation deal with Bayer

US biopharma company ReForm Biologics, which is focussed on developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a new customer. ReForm will perform feasibility studies for Germany’s Bayer utilizing its innovative...